Dostarlimab-gxly Market
Number of pages: 100 | Report Format: PDF | Published date: May 18, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
15.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Cancer Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global dostarlimab-gxly market is expected to register a revenue CAGR of 15.6% during the forecast period from 2023 to 2031.
Dostarlimab-gxly Market Fundamentals
Dostarlimab-gxly, also known by its brand name Jemperli, is a monoclonal antibody medication used to treat certain types of cancer. Dostarlimab-gxly is especially indicated for treating adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment. Dostarlimab-gxly belongs to a class of medications called immune checkpoint inhibitors. It works by blocking the programmed death receptor-1 (PD-1) pathway, a mechanism cancer cells can exploit to evade the immune system. By inhibiting PD-1, dostarlimab-gxly helps restore the immune system’s ability to recognize and attack cancer cells. The approval and use of dostarlimab-gxly are typically guided by specific diagnostic tests to identify patients with dMMR tumors. These tests assess the mismatch repair protein expression level or genetic alterations that indicate the potential responsiveness to dostarlimab-gxly treatment. Dostarlimab-gxly is administered through intravenous infusion. The healthcare provider determines the dosing and treatment schedule based on the patient's condition and therapy response.
The global dostarlimab-gxly industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the dostarlimab-gxly market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the dostarlimab-gxly market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Dostarlimab-gxly Market Dynamics
Dostarlimab-gxly is indicated for treating patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment. Prior to the availability of dostarlimab-gxly, there were limited treatment options for these patients. The drug's approval provides a new treatment avenue, addressing a significant unmet medical need and thus boosting the overall growth of the dostarlimab-gxly market. Moreover, dostarlimab-gxly has received regulatory approvals from health authorities, such as the U.S. Food and Drug Administration (FDA), for its indicated use. These approvals validate its safety and efficacy and allow for its commercialization and availability to eligible patients, driving market adoption and leading to the dostarlimab-gxly market growth. Furthermore, the high unmet medical need for effective treatments for dMMR endometrial cancer and the increasing adoption of precision medicine in cancer treatment are fueling the global dostarlimab-gxly market.
Cost and reimbursement, safety and side effects, and limited patient population are some restraints impeding the overall dostarlimab-gxly market growth.
Dostarlimab-gxly Market Ecosystem
Dostarlimab-gxly Market, by Cancer Type
Dostarlimab-gxly Market, by End User
Dostarlimab-gxly Market by End User
[7567]
The hospital segment dominated the market with the largest revenue share in 2022, owing to the rising prevalence of endometrial cancer. Hospitals are crucial in providing the necessary infrastructure, equipment, and medical personnel to administer the drug to patients safely. Dostarlimab-gxly is administered intravenously through infusion, typically in a hospital or clinical setting. Hospitals, particularly specialized cancer treatment centers, often serve as hubs for oncology care. These centers have the expertise and resources to diagnose, treat, and manage cancer patients, including those who may benefit from dostarlimab-gxly.
The market segmentation sections provide the dostarlimab-gxly market outlook regarding the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as cancer type and end user. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential dostarlimab-gxly market demand opportunities.
Dostarlimab-gxly Market by Region
North America dominated the global dostarlimab-gxly market with the largest revenue share in 2022, owing to the rising prevalence of cancer, robust healthcare infrastructure, high healthcare expenditure, and favorable reimbursement scenarios. According to the National Center for Disease Control and Prevention’s article of September 2022, uterine endometrial cancer is one of the most prominent gynecologic cancers in the United States, with over 60,000 new cases projected in the upcoming year. Additionally, North America has a strong presence in clinical research and participation, including oncology. This participation contributes to the availability of clinical trial data supporting the efficacy and safety of dostarlimab-gxly, further influencing its adoption in the region.
Based on the regions, the global dostarlimab-gxly market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of dostarlimab-gxly industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level dostarlimab-gxly market overview.
Key Components of the Report
Dostarlimab-gxly Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Dostarlimab-gxly Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Dostarlimab-gxly, also known by its brand name Jemperli, is a monoclonal antibody medication used to treat certain types of cancer.
Key players are conducting clinical trials to generate robust data supporting the efficacy and safety of dostarlimab.
North American region will have the largest dostarlimab-gxly market size during the forecast period from 2023 to 2031.
The revenue CAGR of the dostarlimab-gxly market during the forecast period will be 15.6% from 2023 to 2031.
Advancements in precision medicine is the most prominent dostarlimab-gxly industry trend.
The cost and reimbursement, safety and side effects, and limited patient population are some key challenges hampering the growth of the global dostarlimab-gxly market.
Advancements in precision medicine and a growing understanding of tumor biology are growth opportunities in the global dostarlimab-gxly market.
The key player in the dostarlimab-gxly market is GSK plc
The endometrial cancer segment has the highest share in the global dostarlimab-gxly market.
*Insights on financial performance are subject to the availability of information in the public domain